Atlanta and American Bar Associations; Bankruptcy Bar Association of the Southern District of Florida (Former Director); American Bankruptcy Institute.
ISLN:
900551251
Admitted:
1994
University:
University of Florida, B.S.B.A., 1990
Law School:
University of Florida College of Law, J.D., with honors, 1993
Genovese Joblove & Battista, Attorneys at Law Bank Of America Tower At International Place 100 Southeast Second St., 44Th Floor, Miami, FL 33131 3053492300
Licenses:
Florida - Member in Good Standing 1994
Education:
University of Florida, Fredric G. Levin College of Law Degree - JD - Juris Doctor - Law University of Florida Degree - BS - Bachelor of Science - Business Administration
American Bar Association - Member Atlanta Bar Association - Member Atlanta Bar Association - Board of Directors Bankruptcy Bar Association - Member Florida Bar - Member State Bar of Georgia - Member
Atlanta and American Bar Associations Bankruptcy Bar Association of the Southern District of Florida (Former Director) American Bankruptcy Institute.
ISLN:
900551251
Admitted:
1994, Georgia and Florida U.S. District Court, Middle and Northern Districts of Georgia U.S. District Court, Southern and Middle Districts of Florida U.S. Court of Appeals, Eleventh Circuit U.S. Bankruptcy Court, Southern and Middle District of Florida
May 2012 to 2000 Operations ManagerUnited Rentals, Trench Safety Division Jacksonville, FL Jun 2009 to Apr 2012 Branch ManagerCoble Trench Safety Richmond, VA Jun 2008 to Jun 2009 Business Development ManagerMabey Bridge & Shore, Inc
2006 to 2007 Regional Sales ManagerMabey Bridge & Shore, Inc
Jun 2010 to 2000 Pharmaceutical QA / Compliance Consultant and InstructorValidant Scientific Staffing (Contractor) at Patheon Pharmaceuticals Cincinnati, OH Jun 2011 to Aug 2011 AuditorAerotek Scientific Staffing (Contractor) at Schering-Plough / Merck
Jun 2009 to May 2010 Aerotek Scientific Staffing (Contractor)QPSI LLC - Steritek Division
2008 to 2009 Manager, Quality AssuranceElite Laboratories / Pharmaceuticals
2006 to 2008 Manager / Group Leader / QA Associate IV, Quality Assurance and ComplianceGlatt Air Techniques Inc
2000 to 2006 Group Leader / Sr. QA Associate - Quality Assurance and ComplianceSmithKline Beecham
1992 to 2000 Analytical Chemist / Technician - Analytical Research and DevelopmentSmithKline Beecham - now Glaxo-SmithKline Parsippany, NJ 1995 to 1995 Analytical ChemitsSmithKline Beecham
1994 to 1994 Publication and Method Development "SimultaneousSmithKline Beecham
1993 to 1993 Analytical ChemistEthicon, Inc
1991 to 1992 ContractorART International, Inc
1989 to 1991 Project Manager / Analytical Lab Supervisor / QA Engineer / OSHA Coordina tor - R & DJ. L. Prescott Company
1981 to 1988 Facility Quality Control Laboratory Manager / Corporate Quality Assurance Supervisor
Education:
Thomas Edison State College Trenton, NJ Jan 1999 BA in - Chemistry ConcentrationMorris County College Township of Randolph, NJ Jan 1988 AS in ChemistryRutgers College, Rutgers University New Brunswick, NJ Pre - Med
Faculty Practice Associates 17 E 102Nd St, New York, NY 10029 2122416585 (Phone)
Mt Sinai Primary Care 17 E 102Nd St Suite D, New York, NY 10029 2122416585 (Phone)
Certifications:
Internal Medicine, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School Perelman School of Medicine University of Pennsylvania Graduated: 1996 Medical School Hospital Of The University Of Pennsylvania Graduated: 1996
Dr. David T Stern, New York NY - MD (Doctor of Medicine)
Faculty Practice Associates 17 E 102Nd St, New York, NY 10029 2122416585 (Phone)
Mt Sinai Primary Care 17 E 102Nd St Suite D, New York, NY 10029 2122416585 (Phone)
Certifications:
Internal Medicine, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School Vanderbilt University School Of Medicine Graduated: 1989 Medical School Tufts New England Mc Graduated: 1990 Medical School Tufts New England Mc Graduated: 1992 Medical School Palo Alto Va/Stanford Graduated: 1992
Dr. David A Stern, Houston TX - MD (Doctor of Medicine)
Palm Beach Medical Group 4601 N Congress Ave, West Palm Beach, FL 33407 5618404600 (phone), 5618404680 (fax)
Palm Beach Medical Group 500 University Blvd STE 106, Jupiter, FL 33458 5617479600 (phone), 5618404680 (fax)
Education:
Medical School Philadelphia College of Osteopathic Medicine Graduated: 1979
Procedures:
Allergen Immunotherapy Destruction of Benign/Premalignant Skin Lesions Electrocardiogram (EKG or ECG) Pulmonary Function Tests Vaccine Administration
Conditions:
Abdominal Hernia Acne Anxiety Dissociative and Somatoform Disorders Atherosclerosis Atrial Fibrillation and Atrial Flutter
Languages:
English Spanish
Description:
Dr. Stern graduated from the Philadelphia College of Osteopathic Medicine in 1979. He works in West Palm Beach, FL and 1 other location and specializes in Internal Medicine. Dr. Stern is affiliated with John F Kennedy Medical Center North Campus and Jupiter Medical Center.
Name / Title
Company / Classification
Phones & Addresses
Mr David Stern Owner
David Stern Jewelers Jewelers - Retail. Jewelry Buyers
This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0. 1 g/ml plasma to about 250 g/ml plasma or from about 0. 5 g/ml plasma to about 25 g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient.
Method For Inhibiting Tumor Invasion Or Spreading In A Subject
The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.
Nucleic Acid Encoding Bovine Extracellular Rage Binding Protein (En-Rage)
Ann Marie Schmidt - Franklin Lakes NJ David Stern - Great Neck NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C12P 2106
US Classification:
435 691, 4353201, 435325, 536 235
Abstract:
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
David Stern - Great Neck NY Shi Du Yan - New York NY Ann Marie Schmidt - Franklin Lakes NJ Ira Lamster - Wyckoff NJ
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 3800
US Classification:
530324, 530300
Abstract:
The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid- peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid- peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid- peptide with the receptor for advanced glycation endproduct.
Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (Rage) And Mutant App In Brain And Uses Thereof
David M. Stern - Great Neck NY Ann Marie Schmidt - Franklin Lakes NJ Shi Du Yan - New York NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
G01N 3300
US Classification:
800 3, 800 12, 800 18
Abstract:
The invention provides for a non-human transgenic animal whose cells contain a recombinant DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which encodes human receptor for advanced glycation endproducts (RAGE), and (b) a nerve tissue specific promoter operatively linked to a DNA sequence encoding a mutant human amyloid precursor protein hAPP695, hAPP751 and hAPP770 bearing mutations linked to familial Alzheimers disease in humans, wherein said non-human transgenic animal exhibits at least one phenotype from the group consisting of: increased expression of M-CSF gene in cerebral cortex; increased expression of IL-6 gene in cerebral cortex; increased neuronal stress; increased neurotoxicity; neuron loss; increased level of activated form of caspase 3 in brain; and increased level of phosphorylated tau protein in brain.
Extracellular Novel Rage Binding Protein (En-Rage) And Uses Thereof
Ann Marie Schmidt - Franklin Lakes NJ David Stern - Great Neck NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
G01N 3353
US Classification:
435 71, 530324, 530350, 5303881, 5303891
Abstract:
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
Method To Increase Cerebral Blood Flow In Amyloid Angiopathy
The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.
David F. Stern has concentrated his practice in the area of workers’ compensation litigation since graduation from The University of Pittsburgh School of Law. Mr. Stern has been representing injured w...
Tagline:
The Unmistakable Choice in Workers' Compensation and Social Security Disability Law
David Stern
Work:
Slate Magazine - Senior Product Manager
Education:
London School of Economics, Cornell University
David Stern
Work:
Self-Employed (1995) USC - Sr. Mgr. of Operations/Hospitality (2009-2011)
Education:
Culinary Institute of America - Hospitality Management